Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL

Rigel Pharmaceuticals — Technical Presentation (December 2007)

9 slides from Rigel Pharmaceuticals's technical presentation, Dec 4, 2007

  1. Slide 1: Rigel Conference Call - R788 Phase 2 Trial in ITP

    Rigel Conference Call - R788 Phase 2 Trial in ITP December 4, 2007 1:30pm Pacific/4:30pm Eastern

  2. Slide 2: R788 Phase 2 Trial in ITP - Background

    R788 Phase 2 Trial in ITP Background: • Syk is a key kinase enzyme involved in Fc receptor (FcR) and B cell receptor signaling in various inflammatory cells • FcRγ activation and signaling has been implicated in the immune destruction of platelets, a hallmark of ITP • R788, an orally bioavailable sm

  3. Slide 3: R788 Phase 2 Trial in ITP - Study Design

    R788 Phase 2 Trial in ITP - Study Design • Adult patients with chronic refractory ITP • Primary Efficacy: Platelet counts increased by 20K from baseline, to over 30K platelets • Dosing: treated with 75 - 175 mg PO BID of R788 • Duration: 30 days dosing with extension, most responders treated for 20-

  4. Slide 4: Patients Enrolled

    R788 Phase 2 Trial in ITP - Patients Enrolled Baseline characteristics Age (years) median 66 range 31,81 Gender (n) Male 6 • Older population Female 10 Race (n) White or Caucasian 13 • Highly refractory ITP Black or African American Hispanic or Latino 0 1 – ITP for 10 years (median) Asian Other 1 1

  5. Slide 5: Efficacy Results

    R788 Phase 2 Trial in ITP - Efficacy Results • Clinically-significant response was seen in 12/16 (75%) patients – Increased platelet counts – Reduced need for IVIg treatment – Steroid tapering – Durable response (platelet count increased by >20K to at least 30K on at least 75% of study visits) was s

  6. Slide 6: Efficacy Results

    R788 Phase 2 Trial in ITP - Efficacy Results Median Max Platelet Count (in ‘000s) 14 17 14 = Baseline Plt Counts % Visits >30K Plts 100% 48% 0% % Visits >50K Plts 93% 19% 0% %Visits Treated w/ IVIg 0% 3% 53%

  7. Slide 7: Safety

    R788 Phase 2 Trial in ITP - Safety Adverse Reaction N=14 N=16 Nausea 4 Diarrhea 4 SBP increased by >10 4 Drowsiness 3 Weight gain >5 kg 3 Constipation 2 ALT >2x ULN 2 Vomiting 1 Abdominal pain 1 Headache 1 The nausea and vomiting were amenable to treatment with anti-nausea agents.

  8. Slide 8: Broader Clinical Safety Experience

    R788 Broader Clinical Safety Experience • This R788 trial in ITP is part of a broader clinical effort: – Approx. 236 patients have been treated with R788 in Phase 2 trials in:  RA: >140 patients treated at doses of 50/100/150mg BID  Lymphoma: >80 patients treated at doses of 200/250mg BID  ITP: 1

  9. Slide 9: Conclusions

    R788 Phase 2 Trial in ITP - Conclusions This preliminary ITP study found that: • R788 is effective in maintaining adequate platelet counts in some patients with severely refractory ITP • The majority (75%) of patients on drug achieved a clinical response and a subset maintained a durable platelet re

Rigel Pharmaceuticals — Technical Presentation (December 2007) on 6ix